1
|
Allanore Y, Simms R, Distler O,
Trojanowska M, Pope J, Denton CP and Varga J: Systemic sclerosis.
Nat Rev Dis Primers. 1(15002)2015.PubMed/NCBI View Article : Google Scholar
|
2
|
Ntoumazios SK, Voulgari PV, Potsis K,
Koutis E, Tsifetaki N and Assimakopoulos DA: Esophageal involvement
in scleroderma: Gastroesophageal reflux, the common problem. Semin
Arthritis Rheum. 36:173–181. 2006.PubMed/NCBI View Article : Google Scholar
|
3
|
Raja J, Ng CT, Sujau I, Chin KF and
Sockalingam S: High-resolution oesophageal manometry and 24-hour
impedance-pH study in systemic sclerosis patients: Association with
clinical features, symptoms and severity. Clin Exp Rheumatol. 34
(Suppl 100):S115–S121. 2016.PubMed/NCBI
|
4
|
Luciano L, Granel B, Bernit E, Harle JR,
Baumstarck K, Grimaud JC, Bouvier M and Vitton V: Esophageal and
anorectal involvement in systemic sclerosis: A systematic
assessment with high resolution manometry. Clin Exp Rheumatol. 34
(Suppl 100):S63–S69. 2016.PubMed/NCBI
|
5
|
Vischio J, Saeed F, Karimeddini M,
Mubashir A, Feinn R, Caldito G, Striegel K and Rothfield N:
Progression of esophageal dysmotility in systemic sclerosis. J
Rheumatol. 39:986–991. 2012.PubMed/NCBI View Article : Google Scholar
|
6
|
Kaye SA, Siraj QH, Agnew J, Hilson A and
Black CM: Detection of early asymptomatic esophageal dysfunction in
systemic sclerosis using a new scintigraphic grading method. J
Rheumatol. 23:297–301. 1996.PubMed/NCBI
|
7
|
Roman S, Hot A, Fabien N, Cordier JF,
Miossec P, Ninet J and Mion F: Réseau Sclérodermie des Hospices
Civils de Lyon. Esophageal dysmotility associated with systemic
sclerosis: A high-resolution manometry study. Dis Esophagus.
24:299–304. 2011.PubMed/NCBI View Article : Google Scholar
|
8
|
Sharma SK, Adarsh MB, Sinha SK,
Bhattacharya A, Rana S, Singh S and Dhir S: The Gastrointestinal
dysmotility and infections in Systemic Sclerosis-A real world
scenario. Curr Rheumatol Rev. 13:1. 2017.
|
9
|
Lahcene M, Oumnia N, Matougui N, Boudjella
M, Tebaibia A and Touchene B: Esophageal involvement in
scleroderma: Clinical, endoscopic, and manometric features. ISRN
Rheumatol. 2011(325826)2011.PubMed/NCBI View Article : Google Scholar
|
10
|
Arif T, Masood Q, Singh J and Hassan I:
Assessment of esophageal involvement in systemic sclerosis and
morphea (localized scleroderma) by clinical, endoscopic, manometric
and pH metric features: A prospective comparative hospital based
study. BMC Gastroenterol. 15(24)2015.PubMed/NCBI View Article : Google Scholar
|
11
|
Kimmel JN, Carlson DA, Hinchcliff M, Carns
MA, Aren KA, Lee J and Pandolfino JE: The association between
systemic sclerosis disease manifestations and esophageal
high-resolution manometry parameters. Neurogastroenterol Motil.
28:1157–1165. 2016.PubMed/NCBI View Article : Google Scholar
|
12
|
Liu X, Li M, Xu D, Hou Y, Wang Q, Tian Z,
Sun Q and Zeng X: Prevalence and clinical importance of
gastroesophageal reflux in Chinese patients with systemic
sclerosis. Clin Exp Rheumatol. 30 (2 Suppl 71):S60–S66.
2012.PubMed/NCBI
|
13
|
Nagaraja V, McMahan ZH, Getzug T and
Khanna D: Management of gastrointestinal involvement in
scleroderma. Curr Treatm Opt Rheumatol. 1:82–105. 2015.PubMed/NCBI View Article : Google Scholar
|
14
|
Muro Y, Sugiura K, Nitta Y, Mitsuma T,
Hoshino K, Usuda T, Hayashi K, Murase Y, Shimizu M and Matsuo H:
Scoring of reflux symptoms associated with scleroderma and the
usefulness of rabeprazole. Clin Exp Rheumatol. 27 (3 Suppl
54):S15–S21. 2009.PubMed/NCBI
|
15
|
Marie I, Ducrotte P, Denis P, Hellot MF
and Levesque H: Oesophageal mucosal involvement in patients with
systemic sclerosis receiving proton pump inhibitor therapy. Aliment
Pharmacol Ther. 24:1593–1601. 2006.PubMed/NCBI View Article : Google Scholar
|
16
|
Akazawa Y, Fukuda D and Fukuda Y:
Vonoprazan-based therapy for Helicobacter pylori eradication:
Experience and clinical evidence. Therap Adv Gastroenterol.
9:845–852. 2016.PubMed/NCBI View Article : Google Scholar
|
17
|
Hoshino S, Kawami N, Takenouchi N, Umezawa
M, Hanada Y, Hoshikawa Y, Kawagoe T, Sano H, Hoshihara Y, Nomura T
and Iwakiri K: Efficacy of vonoprazan for proton pump
inhibitor-resistant reflux esophagitis. Digestion. 95:156–161.
2017.PubMed/NCBI View Article : Google Scholar
|
18
|
Sakurai Y, Mori Y, Okamoto H, Nishimura A,
Komura E, Araki T and Shiramoto M: Acid-inhibitory effects of
vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10
mg in healthy adult male subjects-a randomised open-label
cross-over study. Aliment Pharmacol Ther. 42:719–730.
2015.PubMed/NCBI View Article : Google Scholar
|
19
|
Rickham PP: Human experimentation. Code of
ethics of the world medical association. Declaration of Helsinki.
Br Med J. 2(177)1964.PubMed/NCBI View Article : Google Scholar
|
20
|
Kusano M, Shimoyama Y, Sugimoto S,
Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H,
Ino K, et al: Development and evaluation of FSSG: frequency scale
for the symptoms of GERD. J Gastroenterol. 39:888–891.
2004.PubMed/NCBI View Article : Google Scholar
|
21
|
LeRoy EC, Black C, Fleischmajer R,
Jablonska S, Krieg T, Medsger TA Jr, Rowell N and Wollheim F:
Scleroderma (systemic sclerosis): Classification, subsets and
pathogenesis. J Rheumatol. 15:202–205. 1988.PubMed/NCBI
|
22
|
Danjo A, Yamaguchi K, Fujimoto K, Saitoh
T, Inamori M, Ando T, Shimatani T, Adachi K, Kinjo F, Kuribayashi
S, et al: Comparison of endoscopic findings with symptom assessment
systems (FSSG and QUEST) for gastroesophageal reflux disease in
Japanese centres. J Gastroenterol Hepatol. 24:633–638.
2009.PubMed/NCBI View Article : Google Scholar
|
23
|
Johnson LF and Demeester TR:
Twenty-four-hour pH monitoring of the distal esophagus. A
quantitative measure of gastroesophageal reflux. Am J
Gastroenterol. 62:325–332. 1974.PubMed/NCBI
|
24
|
Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali
CP, Roman S, Smout AJ and Pandolfino JE: International High
Resolution Manometry Working Group. The Chicago Classification of
esophageal motility disorders, v3.0. Neurogastroenterol Motil.
27:160–174. 2015.PubMed/NCBI View Article : Google Scholar
|
25
|
Miwa H, Yokoyama T, Hori K, Sakagami T,
Oshima T, Tomita T, Fujiwara Y, Saita H, Itou T, Ogawa H, et al:
Interobserver agreement in endoscopic evaluation of reflux
esophagitis using a modified Los Angeles classification
incorporating grades N and M: A validation study in a cohort of
Japanese endoscopists. Dis Esophagus. 21:355–363. 2008.PubMed/NCBI View Article : Google Scholar
|
26
|
Medsger TA Jr, Bombardieri S, Czirjak L,
Scorza R, Della Rossa A and Bencivelli W: Assessment of disease
severity and prognosis. Clin Exp Rheumatol. 21 (4 Suppl
30):S42–S46. 2003.PubMed/NCBI
|
27
|
Thonhofer R, Siegel C, Trummer M and
Graninger W: Early endoscopy in systemic sclerosis without
gastrointestinal symptoms. Rheumatol Int. 32:165–168.
2012.PubMed/NCBI View Article : Google Scholar
|
28
|
Kusano M, Hosaka H, Kawada A, Kuribayashi
S, Shimoyama Y, Kawamura O and Moki F: Development and evaluation
of a modified frequency scale for the symptoms of gastroesophageal
reflux disease to distinguish functional dyspepsia from non-erosive
reflux disease. J Gastroenterol Hepatol. 27:1187–1191.
2012.PubMed/NCBI View Article : Google Scholar
|
29
|
Kasugai K, Funaki Y, Izawa S, Ogasawara N
and Sasaki M: Non-erosive reflux disease (NERD). Nihon Rinsho.
74:1351–1356. 2016.PubMed/NCBI(In Japanese).
|
30
|
Miyazaki H, Igarashi A, Takeuchi T, Teng
L, Uda A, Deguchi H, Higuchi K and Tango T: Vonoprazan versus
proton-pump inhibitors for healing gastroesophageal reflux disease:
A systematic review. J Gastroenterol Hepatol. 34:1316–1328.
2019.PubMed/NCBI View Article : Google Scholar
|
31
|
Furuta T, Shirai N, Xiao F, Ohashi K and
Ishizaki T: Effect of high-dose lansoprazole on intragastic pH in
subjects who are homozygous extensive metabolizers of cytochrome
P4502C19. Clin Pharmacol Ther. 70:484–492. 2001.PubMed/NCBI View Article : Google Scholar
|
32
|
Kagami T, Sahara S, Ichikawa H, Uotani T,
Yamade M, Sugimoto M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, et
al: Potent acid inhibition by vonoprazan in comparison with
esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol
Ther. 43:1048–1059. 2016.PubMed/NCBI View Article : Google Scholar
|
33
|
Jenkins H, Sakurai Y, Nishimura A, Okamoto
H, Hibberd M, Jenkins R, Yoneyama T, Ashida K, Ogama Y and
Warrington S: Randomised clinical trial: Safety, tolerability,
pharmacokinetics and pharmacodynamics of repeated doses of TAK-438
(vonoprazan), a novel potassium-competitive acid blocker, in
healthy male subjects. Aliment Pharmacol Ther. 41:636–648.
2015.PubMed/NCBI View Article : Google Scholar
|
34
|
Iwakiri K, Sakurai Y, Shiino M, Okamoto H,
Kudou K, Nishimura A, Hiramatsu N, Umegaki E and Ashida K: A
randomized, double-blind study to evaluate the acid-inhibitory
effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump
inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol.
10:439–451. 2017.PubMed/NCBI View Article : Google Scholar
|
35
|
Basilisco G, Carola F, Vanoli M, Bianchi P
and Barbera R: Oesophageal acid clearance in patients with systemic
sclerosis: Effect of body position. Eur J Gastroenterol Hepatol.
8:205–209. 1996.PubMed/NCBI View Article : Google Scholar
|
36
|
Larsson H, Hakanson R, Mattsson H, Ryberg
B, Sundler F and Carlsson E: Omeprazole: Its influence on gastric
acid secretion, gastrin and ECL cells. Toxicol Pathol. 16:267–272.
1988.PubMed/NCBI View Article : Google Scholar
|
37
|
Laria A, Zoli A, Gremese E and Ferraccioli
GF: Proton pump inhibitors in rheumatic diseases: Clinical
practice, drug interactions, bone fractures and risk of infections.
Reumatismo. 63:5–10. 2011.PubMed/NCBI View Article : Google Scholar
|
38
|
Perez MO, Neves EF, Bortolai CB,
Sampaio-Barros PD, Andrade DC and Seguro LP: Hypomagnesaemia and
hypocalcaemia in a patient with systemic sclerosis: Role of proton
pump inhibitors. Clin Exp Rheumatol. 32 (6 Suppl 86):S225–S227.
2014.PubMed/NCBI
|
39
|
Sheehan NJ: Dysphagia and other
manifestations of oesophageal involvement in the musculoskeletal
diseases. Rheumatology (Oxford). 47:746–752. 2008.PubMed/NCBI View Article : Google Scholar
|